Bortezomib is effective in primary plasma cell leukemia

Primary plasma cell leukemia and autologous stem cell transplantation

“…25,26 Newer antimyeloma agents, including the group of immunomodulating drugs and proteasome inhibitors, also offer promise, with one small series reporting responses in four patients. 27 Interestingly, this series included a patient who experienced tumor lysis syndrome, which was also described in one case report. 28 In conclusion, our series highlights inadequacies in the current management of PCL and emphasizes the need for new and cooperative approaches to this rare but highly aggressive disorder.…”

Primary plasma cell leukemia followed by testicular plasmacytoma

“…Bortezomib is a proteasome inhibitor successfully used for the therapy of multiple myeloma even in patients with extraosseous disease, now experimented in primary and secondary PCL. In this regard, the information are still limited [14][15][16][17], but recently Musto et al [17] described 12 PCL (8 primary and 4 secondary) treated with bortezomib-containing regimen, obtaining promising results, with an overall response rate of 92% (5 PR, 4 VGPR, 2 CR), and a median survival of 8 months. Despite the use of bortezomib, in our case, the disease rapidly spread, with the involvement of unusual sites.…”

Lenalidomide, Melphalan, and Prednisone Association Is an Effective Salvage Therapy in Relapsed Plasma Cell Leukaemia

“…The median overall survival with conventional therapy is about 7–14 months, while even after stem cell transplantation the outcome remains disappointing [3]. Recently, it has been demonstrated that bortezomib may be also effective and safe in the treatment of PCL [4, 5]. A single case report evidenced the effectiveness of the association of prednisone and lenalidomide in relapsed PCL [6].…”